双膦酸盐使用与卒中风险的关联:一项Meta分析
本Meta分析纳入21项研究共741274名参与者,评估双膦酸盐使用与卒中风险的关联。总体合并RR=0.87(95%CI 0.76-0.99,p=0.048),仅达边缘显著,异质性高(I²=83.7%);随机对照试验亚组合并RR=0.93(95%CI 0.76-1.13,p=0.462)无显著关联。
要点
- 双膦酸盐使用与卒中风险降低相关,但仅达边缘显著(合并RR=0.87,95%CI 0.76-0.99,p=0.048)。
- 随机对照试验亚组分析未发现显著关联(合并RR=0.93,95%CI 0.76-1.13,p=0.462)。
- 研究间异质性高(I²=83.7%),需未来高质量研究确定因果关系。
核心结论
- 双膦酸盐使用可能与较低的卒中风险相关,但当前证据因统计边缘显著和高异质性无法得出确定结论。
- 未来需要研究尤其是随机对照试验来评估因果关系。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Scopus和Cochrane图书馆从建库至2022年1月3日,并于2022年8月22日用PubMed更新检索。
- 共纳入21项研究(7项随机对照试验和14项观察性研究),涉及741274名参与者。
- 由两名或以上评审员独立筛选文章、提取数据并评估研究质量,采用随机效应模型合并卒中相对风险(RR)。
主要发现
- 总体双膦酸盐使用与卒中风险降低相关,但仅达边缘显著(合并RR=0.87,95%CI 0.76-0.99,p=0.048),研究间异质性高(I²=83.7%)。
- 随机对照试验亚组分析显示双膦酸盐使用与卒中风险无显著关联(合并RR=0.93,95%CI 0.76-1.13,p=0.462;I²=13.4%)。
局限性
- 总体合并结果仅达边缘显著(p=0.048)。
- 研究间异质性高(I²=83.7%)。
- 当前证据因边缘显著和高异质性无法得出确定结论。
- 未来需要研究尤其是随机对照试验来评估因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Previous studies have suggested that bisphosphonates may reduce stroke risk. This meta-analysis, which included 21 studies with 741,274 participants, revealed that bisphosphonates might be associated with lower stroke risk. However, evidence derived from randomized controlled trials identified no statistically significant association. Future high-quality studies are still required to determine causality. PURPOSE: Whether bisphosphonates may reduce the risk of stroke remains inconclusive. We conducted a systematic review and meta-analysis to evaluate the association between bisphosphonate use and the risk of stroke based on up-to-date evidence. METHODS: We searched for studies evaluating the effects of bisphosphonate on the risk of stroke from inception until January 3, 2022, on PubMed, Embase, Scopus, and Cochrane libraries and updated our search until August 22, 2022, using PubMed to identify any new potential published studies. Two or more reviewers independently screened articles, extracted data, and assessed the study quality. We retrieved the data to synthesize the pooled relative risk (RR) of stroke associated with bisphosphonate use compared with controls; random-effects models were used for meta-analysis. RESULTS: A total of 21 studies (7 randomized controlled trials [RCTs] and 14 observational studies) involving 741,274 participants were included in our meta-analysis. Overall, bisphosphonate use was associated with a lower risk of stroke, but the result was only borderline significant (pooled RR = 0.87, 95% confidence interval [CI]: 0.76-0.99, p = 0.048), and high between-study heterogeneity was found (I2 = 83.7%). Subgroup analyses showed that the evidence derived from RCTs suggested no significant association between bisphosphonate use and stroke risk (pooled RR = 0.93, 95% CI: 0.76-1.13, p = 0.462; I2 = 13.4%). CONCLUSION: Our results suggest that bisphosphonate use is associated with a lower risk of stroke. However, the current evidence does not lead to a definite conclusion due to the borderline statistical significance and high between-study heterogeneity. Future studies, especially RCTs, are necessary to assess causality.
引用
- Lin SM, Lin JY, Tu YK, et al. Association between bisphosphonate use and stroke risk: a meta-analysis. Osteoporos Int. 2023. PMID: 37249610. doi:10.1007/s00198-023-06781-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。